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Background: A predominant feature of asthma is an accelerated rate of decline in forced expi-
ratory volume in 1 s (FEV1), but data on the variability and factors associated with this change
in patients with controlled asthma are largely unknown.
Methods: 140 patients with controlled asthma were enrolled based on the Global Initiative for
Asthma guidelines. We examined the data of a prospective analysis of the association between
asthma control and change in FEV1 over time.
Results: A 3-year follow-up assessment was completed in 128 patients. The mean rate of
change in FEV1 was a decline of 22.2 mL yr
1, with significant variation in the levels of change.
The between patient standard deviation for the rate of decline was 34.1 mL yr1. We next clas-
sified the subjects of less than the 25th percentile as rapid decliners, and greater than the 25th
percentile as non-rapid decliners. The decrease in the Asthma Control Test score over a 3-year
period was higher for rapid decliners than that for non-rapid decliners (p < 0.001). The rapid
decliner was more likely to be older, to have higher levels of FeNO, and to have had severe
exacerbations during the study. Patients with severe exacerbations had a greater annual
decline in FEV1 compared to patients with no exacerbations (13.6 vs. 53.2 mL yr1,
p < 0.0001).est; CRS, chronic rhinosinusitis; FeNO, exhaled nitric oxide fraction; GERD, gastro-esophageal reflux
thma; ICS, inhaled corticosteroids.
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Changes in FEV1 in controlled asthma at baseline 977Conclusions: Among patients with controlled asthma at baseline, the rate of change in FEV1 is
highly variable. Severe exacerbations are strongly associated with a rapid loss of lung function.
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Asthma is generally acknowledged as being a highly
reversible inflammatory disorder of the airways [1], and the
majority of cases can be controlled with usual therapy such
as inhaled corticosteroids (ICS) [1e4]. Many studies have
shown a reduction in airway inflammation, improvement in
asthma symptoms and pre-bronchodilator lung function by
treatment with ICS [2e4]. However, it is still controversial
whether long-term preventive therapy with ICS can alter
the natural history of airway obstructive changes in asth-
matic patients [5]. A predominant feature of asthma is an
accelerated rate of decline in forced expiratory volume in
1 s (FEV1) [6], but few longitudinal studies of patient co-
horts have provided detailed data regarding the rate of
FEV1 decline in asthma patients on preventive therapy with
ICS [7e10].
Multiple factors have been associated with the excessive
loss of lung function in patients with asthma, including
male gender [11], older age [10,11], smoking history [11],
longer disease duration [11], aspirin sensitivity [11], exac-
erbations [9,10], and higher levels of exhaled nitric oxide
fraction (FeNO) [12,13]. However, most of these factors
were found in studies that targeted patients with severe or
difficult-to-treat asthma [10e13]. To date, the factors
associated with the rapid loss of FEV1 in patients with non-
severe asthma are largely unknown.
The FLOAT (Factors affecting the Long-term Asthma
Therapy) study is a 3-year, prospective, cohort investiga-
tion of non-smoking patients with controlled asthma based
on the Global Initiative for Asthma (GINA) guidelines [1].
Multiple factors such as age, gender, body mass index,
atopy, smoking history, comorbidities, disease duration,
and blood eosinophil counts were assessed at baseline, and
asthma control, medication use, adherence to the therapy,
severe exacerbations, forced vital capacity (FVC), FEV1,
and FeNO were surveyed during the follow-up period. The
present study is a prospective analysis of the association
between asthma control and the rate of change in post-
bronchodilator FEV1 over time in patients with controlled
asthma at baseline. The factors that might associate with
the rapid decline in FEV1 were also investigated.Methods
Study design and patients
The characteristics of the present cohort have been pub-
lished previously [14]. Briefly, a population of 250 adults
with stable asthma following treatment with ICS with or
without inhaled long-acting b2-agonist, leukotriene recep-
tor antagonist, or theophylline for more than 4 years was
evaluated using a standardized protocol from June 2010 toNovember 2010 [14]. Current smokers and patients with
>10 pack-year smoking history were not included in this
analysis. Also, patients with poor adherence to the treat-
ment (defined as <80% adherence calculated by dividing
the number of days supplied for a medication by the
number of days between the visits) or with other pulmonary
diseases such as chronic obstructive pulmonary disease,
were excluded [14]. In this 3-year prospective cohort study,
140 patients with controlled asthma aged over 25 years old
were selected based on the GINA guidelines (Twice or less/
week daytime symptoms, no limitation of daily activities,
no nocturnal symptoms, twice or less/week need for re-
liever, normal lung function (70% FEV1/forced vital ca-
pacity (FVC) ratio and 80% FEV1% of predicted), no
exacerbation in the previous one year) [1]. 78 patients with
partly controlled asthma, 26 patients with uncontrolled
asthma, and 6 patients under the age of 25 years old were
not included in the current analysis. The study subjects
were followed with Asthma Control Test (ACT), spirometry,
and FeNO at every scheduled visit. Medical records
including medication use, adherence to the treatment, and
comorbidities such as allergic rhinitis, chronic rhinosinusitis
(CRS), or gastro-esophageal reflux disease (GERD) were
obtained. All comorbidities were identified by specialists on
the basis of the current guidelines [15,16]. Blood eosinophil
numbers, and serum specific immunoglobulin E (IgE) for
common inhaled allergens (house dust mite, cedar,
ragweed, cocksfoot, dog, and cat) were examined. Positive
specific IgE to at least one allergen was assumed to confirm
the presence of atopy. Patients attended the clinic on a
regular basis during the follow-up (generally four times per
year) and unscheduled visits were made if their asthma
condition was deteriorating. ICS doses and use of other
asthma controllers were not fixed during the follow-up
period since this was a purely observational study. The
study was approved by the ethics committee of Wakayama
Medical University (IRB #526) and registered with the Uni-
versity Hospital Medical Information Network (UMIN
000012105: FLOAT study). Informed written consent was
obtained from each participant.
Study assessments
The FVC and FEV1 values were measured using a dry rolling
seal spirometer. Both measurements were made before and
30 min after inhalation of 400 mg of salbutamol. The post-
bronchodilator FEV1 values were selected to reflect loss
of lung function as in other studies following lung function
in patients with asthma over time [7,8]. The mean annual
changes in FEV1 over a 3-year period were estimated for
each subject by fitting a least-square regression line. The
random slope was based on time of FEV1 assessment. Lung
function data during periods of worsening asthma were not
included (between 28 days before and 28 days after the
Table 1 Baseline characteristics of study subjects.
Age (yrs) 43.7  13.6
Gender (female/male) 86/42
Body mass index (kg/m2) 22.1  3.9
Smoking status (Never/Ex), n 94/34
Atopy, n (%) 102 (79.7)
Allergic rhinitis, n (%) 93 (72.7)
Chronic rhinosinusitis, n (%) 19 (14.8)
Gastro-esophageal reflux disease, n (%) 17 (13.3)
Asthma duration (yrs) 10.4  3.2
Duration of asthma treatment (yrs) 8.8  2.7
Dose of inhaled corticosteroids (mg/day)a 331  111
Use of inhaled long-acting b2-agonist, n (%) 61 (47.7)
Use of leukotriene receptor antagonist, n (%) 17 (13.3)
Use of theophylline, n (%) 9 (7.0)
Asthma Control Test (points) 23.2  1.0
FVC (mL) 3510  779
FVC% of predicted (%) 103.5  9.6
FEV1 (mL) 2835  646
FEV1/FVC ratio (%) 80.9  7.1
FEV1% of predicted (%) 97.0  7.8
Blood eosinophil counts (cells/mL) 242  213
Exhaled nitric oxide fraction (ppb) 28.8  17.4
Data are presented as means  SD unless otherwise stated.
All spirometric data were determined after inhalation of 400 mg
of salbutamol.
a Inhaled corticosteroids, expressed as fluticasone propionate
equivalent.
978 K. Matsunaga et al.start of an exacerbation). The FeNO was measured by an
online electrochemical NO analyzer (NIOX MINO; Aerocrine,
Solna, Sweden) as previously described [17]. The ACT is a
questionnaire that assesses the asthma condition. A vali-
dated Japanese translation has been used in earlier studies
in Japan [14,18].
Severe asthma exacerbations
A recent American Thoracic Society (ATS)/European Res-
piratory Society (ERS) task force report was used to define
exacerbations as events identified to be outside the pa-
tient’s usual range of day-to-day asthma variation, and
requiring a change in controller treatment [19]. Based on
medical history, physical examination, and functional as-
sessments such as PEF or FEV1 and oxygen saturation, the
physician then labeled the event as an asthma exacerba-
tion. A severe exacerbation was defined as worsening
asthma requiring at least 3 days treatment with systemic
corticosteroids, or as a hospitalization due to asthma [19].
We used a standardized management protocol to ensure
uniformity in the care settings. According to the current
guidelines, 0.5 mg/kg prednisolone was given daily for 5e10
days if the rapid-acting inhaled b2-agonist therapy failed to
achieve an immediate response, or if the episode was se-
vere [1]. A maximum of one exacerbation per 2-month
period was counted.
Statistical analysis
All data were expressed as mean values  SD for continuous
variables. For categorical variables, the numbers of obser-
vations and percentages were given in each category. The
KolmogoroveSmirnov test was used to assess the normality
assumption of the annual rate of change in FEV1. In this
study, we classified the subjects into two groups based on
the magnitude of change in FEV1. We labeled those of less
than the 25th percentile as rapid decliners, and greater
than the 25th percentile as non-rapid decliners. The clinical
and demographic characteristics of these two groups were
compared using the Chi-squared test, unpaired t-tests, and
ManneWhitney U tests. Spearman’s correlation analysis was
used to assess the correlation. A p-value of <0.05 was
considered statistical significant.Figure 1 Distribution of annual rates of change in forced
expiratory volume in 1 s (FEV1) in patients with controlled
asthma at baseline. Each bar represents changes in FEV1 of
10 mL per year.Results
The 3-year follow-up assessment was completed in 128
patients. The 12 dropouts were from either non-adherence
or because lost to follow-up. The baseline characteristics
are listed in Table 1. The subjects consisted of 42 males and
86 females with an average age of 43.7 years. Fig. 1 shows
the distribution of the estimated annual rates of decline in
FEV1 (DFEV1). A total of 1644 FEV1 measurements were
analyzed. Normality assumptions were met for the change
in FEV1 (KolmogoroveSmirnov test, p > 0.10). The mean
rate of change in FEV1 was a decline of 22.2 mL yr
1, with
significant variation in the levels of change. The between
patient standard deviation for the rate of decline was
34.1 mL yr1.We next classified the subjects of less than the 25th
percentile as rapid decliners (n Z 33, 64.9 mL yr1), and
greater than the 25th percentile as non-rapid decliners
(n Z 95, 7.4 mL yr1). All rapid decliners had an esti-
mated rate of decline in FEV1 of more than 40 mL yr
1. The
baseline characteristics of these two groups are presented
in Table 2. The ACT score, FVC, and FEV1 were similar be-
tween the groups, although the rapid decliners were more
likely to be older and to have higher levels of FeNO
compared to the non-rapid decliners (all p < 0.05). Table 3
shows the clinical characteristics during the follow-up
period and at the end of the study. The rapid decliners
Table 2 Baseline characteristics subdivided by the magnitude of change in forced expiratory volume in 1 s.
Characteristics Non-rapid decliner (n Z 95)a Rapid decliner (n Z 33)b p Value
Age (yrs) 42.3  13.8 47.8  12.3 <0.05
Gender (female/male) 64/31 22/11 0.94
Body mass index (kg/m2) 21.8  3.7 22.8  5.1 0.24
Smoking status (Never/Ex), n 72/23 22/11 0.31
Atopy, n (%) 75 (78.9) 27 (81.8) 0.73
Allergic rhinitis, n (%) 69 (72.6) 24 (72.7) 0.99
Chronic rhinosinusitis, n (%) 11 (11.6) 8 (24.2) 0.08
Gastro-esophageal reflux disease, n (%) 12 (12.6) 5 (15.2) 0.72
Asthma duration (yrs) 10.3  3.2 10.7  3.3 0.37
Duration of asthma treatment (yrs) 8.7  2.6 8.8  2.3 0.72
Dose of inhaled corticosteroids (mg/day)c 322  113 357  103 0.12
Use of inhaled long-acting b2-agonist, n (%) 44 (46.3) 17 (51.5) 0.61
Use of leukotriene receptor antagonist, n (%) 13 (13.7) 4 (12.1) 0.82
Use of theophylline, n (%) 5 (5.3) 4 (12.1) 0.18
Asthma Control Test (points) 23.2  1.0 23.3  1.1 0.66
FVC (mL) 3520  747 3481  875 0.80
FVC% of predicted (%) 103.3  9.4 103.9  10.6 0.76
FEV1 (mL) 2864  635 2750  678 0.38
FEV1/FVC ratio (%) 81.4  7.0 79.3  7.2 0.14
FEV1% of predicted (%) 96.9  7.7 97.6  8.2 0.66
Blood eosinophil counts (cells/mL) 222  187 299  270 0.07
Exhaled nitric oxide fraction (ppb) 26.3  15.8 35.9  15.9 <0.05
Data are presented as means  SD unless otherwise stated. p values compared between the groups.
All spirometric data were determined after inhalation of 400 mg of salbutamol.
a Less than the 25th percentile based on the magnitude of change in FEV1.
b Greater than the 25th percentile based on the magnitude of change in FEV1.
c Inhaled corticosteroids, expressed as fluticasone propionate equivalent.
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despite treatment with higher doses of ICS. In the non-rapid
decliners, 10.5% of patients experienced at least one se-
vere exacerbation with a mean rate of 0.05 yr1. In
contrast, 54.5% of the rapid decliners experienced severe
exacerbations, with a mean rate of 0.49 yr1. As shown in
Fig. 2, the decrease in ACT score over a 3-year period was
significantly higher for rapid decliners than that for non-
rapid decliners (p < 0.001). At the end of the study, a
total of 21 participants (16.4%) were defined as partly
controlled asthma based on GINA (6.3% of the non-rapid
decliners and 45.5% of the rapid decliners). During the
entire study period, there were no cases classified as un-
controlled asthma.
As shown in Fig. 3, patients with severe exacerbations had
a greater annual decline in FEV1 (no exacerbation,
13.6mLyr1; exacerbations, 53.2mLyr1; p< 0.0001). Also,
age and FeNO showed a weak but significant correlation with
the rate of decline in FEV1 (rZ 0.22, p< 0.05, and rZ 0.21,
p < 0.05, respectively). However, no association between
the age and FeNO levels at baseline and later severe exac-
erbations was observed in the current study.Discussion
In this prospective cohort study of patients with controlled
asthma at baseline, we showed that the average rate of
change in FEV1 over a 3-year period was a decline of22.2 mL yr1. The rate of decline in FEV1 was highly vari-
able, with a Gaussian distribution. When we dichotomized
the study subjects based on the magnitude of change in
FEV1, worsening of asthma control was more evident in the
patients with rapid decline in FEV1. Severe exacerbations
were strongly associated with a rapid loss of lung function
that occurred over time despite regular preventive therapy
with ICS.
It is known that uncontrolled asthma is highly predictive
of persistent loss of lung function [11,20]. However, the
natural history of airway obstructive changes in patients
with controlled asthma is not fully understood. Our study
showed that the average rate of decline in FEV1 among
patients with controlled asthma at baseline was not
significantly different from that in the general adult pop-
ulation (i.e. 18.7 mL yr1) [21]. Although asthma is
considered to be a progressive disease, only 26% of patients
had an estimated rate of decline in FEV1 of more than
40 mL yr1. The relatively mild declines in lung function
observed in the current study are not substantially
different from those reported in the Copenhagen City Heart
Study [9], in which the mean rate of FEV1 decline among
patients receiving ICS over a 10-year period was 25 mL yr1.
Although all study subjects were controlled asthma at
baseline, the rate of change in FEV1 was highly variable.
This phenomenon could not be fully explained by the evi-
dence that ICS therapy is associated with an attenuation of
the decline in lung function [8,9,22]. The progression of
airway obstruction in asthma is believed to be a
Table 3 Clinical characteristics during follow-up period and at the end of the study.
Characteristics Non-rapid decliner
(n Z 95)
Rapid decliner
(n Z 33)
p Value
Follow-up period
Duration of the follow-up (years) 3.0  0.1 3.0  0.2 0.90
Number of pulmonary function test (times) 12.7  3.1 13.0  3.7 0.72
Use of inhaled corticosteroids (mg/day)a 95 (100.0) 33 (100.0) 1.00
Dose of inhaled corticosteroids (mg/day)b,c 325  109 377  91 <0.05
Use of inhaled long-acting b2-agonist, n (%)a 43 (45.3) 20 (60.7) 0.13
Use of leukotriene receptor antagonist, n (%)a 10 (10.5) 6 (18.2) 0.26
Use of theophylline, n (%)a 5 (5.3) 4 (12.2) 0.19
Number of patients with severe exacerbation, n (%) 10 (10.5) 18 (54.5) <0.0001
Annual exacerbation rate (events/yr)b 0.05  0.14 0.49  0.62 <0.0001
At the end of the study
Asthma Control Test (points) 23.3  1.7 22.1  1.8 <0.001
Number of patients with Asthma Control Test <20, n (%) 2 (3.2) 4 (12.1) <0.05
FVC (mL) 3471  774 3228  902 0.14
FVC% of predicted (%) 101.7  10.5 95.8  10.8 <0.01
FEV1 (mL) 2835  651 2491  671 <0.05
FEV1/FVC ratio (%) 81.8  7.1 77.6  8.4 <0.01
FEV1% of predicted (%) 95.7  8.5 88.0  9.5 <0.001
Annual rates of decline in FEV1 (mL yr
1) 7.4  24.3 64.9  18.7 <0.0001
Number of patients with FEV1 <80%, n (%) 3 (3.2) 6 (18.2) <0.005
Number of patients with controlled asthma, n (%)d 89 (93.7) 18 (54.5) <0.0001
Number of patients with partly controlled asthma, n (%)d 6 (6.3) 15 (45.5) <0.0001
Number of patients with uncontrolled asthma, n (%)d 0 (0.0) 0 (0.0) 1.00
Data are presented as means  SD unless otherwise stated. p values compared between the groups.
a Usage rate of medications during follow-up period.
b Mean values during follow-up period.
c Inhaled corticosteroids, expressed as fluticasone propionate equivalent.
d GINA-defined asthma control levels.
980 K. Matsunaga et al.consequence of structural and functional changes in the
airways, possibly due to abnormal injury and repair re-
sponses of the airway tissue [23,24]. Severe exacerbations
are periods of excess pathological and physiological
changes in the airways that are thought to promote airway
remodeling. Indeed, some studies suggested that inter-
mittent periods of worsening airway inflammation duringFigure 2 Changes in Asthma Control Test score during
follow-up period. The error bars represent 95% confidence
intervals.exacerbations may enhance airway remodeling leading to
accelerated declines in lung function [8,25]. Also, excess
bronchoconstriction often occurs during exacerbations and
this mechanical stress has been suggested to promote
structural changes in the airways [26,27]. In the presentFigure 3 Estimated annual decline in forced expiratory vol-
ume in 1 s (FEV1) according to the presence or absence of se-
vere exacerbations. The error bars represent 95% confidence
intervals.
Changes in FEV1 in controlled asthma at baseline 981study, severe exacerbations were strongly associated with
the rapid loss of lung function, and possibly, increased
airway structural changes. Also, the rapid loss of FEV1 was
involved in the worsening of ACT score. These data suggest
that the prevention of exacerbations might be critical for
maintaining normal lung function and asthma control. Our
study also showed that the rapid decliners were more likely
to be older and to have higher levels of FeNO. These as-
sociations were weak, but our data support those of pre-
vious studies describing that sputum eosinophils and FeNO
facilitate the prediction of rapid loss of lung function in
patients with asthma [12,28].
There are several possible explanations for the severe
decline in lung function in some study patients. One
possible explanation may be inadequate steroid therapy.
However, the greater loss of lung function in patients on
higher doses of ICS is difficult to explain on this basis. Poor
adherence with therapy is possible, but patients whose
adherence was <80% based on the prescription refill data
were excluded from the analysis. This study had several
limitations. First, all the patients in this cohort study
received treatment for asthma, and the use of asthma
controllers was not fixed. Thus, it is possible that treatment
could have affected the rate of decline in FEV1. Although
not all asthma controllers have been shown to reduce the
loss of lung function, several studies have shown that
intervention with ICS is associated with an attenuation of
the decline in FEV1 [8,9,22]. An estimated 25% of the pa-
tients assessed in our study had improved lung function
during the study period. Whether this represents an ex-
pected statistical distribution or a true response to treat-
ment is unknown. Next, the effects of only severe
exacerbations on lung function change were examined.
Thus, our study might have caused an underestimation of
the true overall effects. We chose not to include mild ex-
acerbations since asthma is a heterogeneous condition and
mild asthma variation is difficult to identify precisely.
Nevertheless, this single center study had the advantage of
ensuring uniformity in the assessment of worsening asthma.
In conclusion, our data showed that the average decline
in FEV1 of patients with controlled asthma at baseline was
not significantly different from that in the general adult
population. However, the rate of change in FEV1 was highly
variable and severe exacerbations of asthma were strongly
associated with a rapid loss of lung function, suggesting
that the prevention of exacerbations could have a pivotal
role in the attenuation of the progression of airway
obstruction.
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